Urocross Expander System (UES-2018-C1)
Device Facts
| Record ID | K261342 |
|---|---|
| Device Name | Urocross Expander System (UES-2018-C1) |
| Applicant | Prodeon Medical, Inc. |
| Product Code | QKA · Gastroenterology, Urology |
| Decision Date | Jun 22, 2026 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 876.5510 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Urocross Expander System is intended to relieve urinary outflow obstruction. The Urocross Expander System is indicated for the treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) in men ≥ 45 years old. The Urocross Expander Implant is indicated for an indwell duration of up to 6 months.
Device Story
Temporary implantable urethral opening system; treats BPH-related LUTS. System comprises nitinol tissue expander preloaded in catheter delivery system. Physician advances delivery system through cystoscope (flexible or rigid) into prostatic urethra; deploys implant under cystoscopic visualization. Implant radial force pushes lateral lobes apart; increases prostatic urethral lumen opening; improves urine flow. Implant remains in situ up to 6 months; retrieved via Prodeon Urethral Sheath System or standard cystoscopic graspers. Benefits include relief of urinary outflow obstruction. Subject device adds tether mechanism for controlled release and separate irrigation connector/stopcock compared to predicate.
Clinical Evidence
Bench testing only. Performance testing included dimensional analysis, irrigation, trackability, deployment force/accuracy, tensile strength, leak testing, radial force, and catheter integrity. Biocompatibility testing per ISO 10993-5, -10, and -23. Shelf-life validated per ASTM F1980-16, F1886/F1886M-16, F2096-11, and F88/F88M-15. Sterilization validated per ISO 11135:2014.
Technological Characteristics
Nitinol tissue expander; delivery system materials include Pebax, stainless steel, polyimide, PTFE, polycarbonate, HDPE. Dimensions: 20 mm length x 18 mm diameter. Mechanical expansion principle. Sterile, single-use, EtO sterilized. Biocompatibility per ISO 10993-1. Standards: ISO 10555-1:2013, ISO 20696:2018, ASTM F1980-16, ASTM F1886/F1886M-16, ASTM F2096-11, ASTM F88/F88M-15, ISO 11135:2014.
Indications for Use
Indicated for treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) in men ≥ 45 years old. Implant indwell duration up to 6 months.
Regulatory Classification
Identification
A temporarily-placed urethral opening system for symptoms of benign prostatic hyperplasia (BPH) is a prescription use device that is inserted transurethrally and deployed at the prostate. The implant is designed to increase prostatic urethral patency by increasing prostatic opening. It is intended for the treatment of symptoms due to urinary outflow obstruction secondary to BPH in men.
Special Controls
*Classification.* Class II (special controls). The special controls for this device are:(1) Clinical performance testing with the device under anticipated conditions of use must evaluate improvement in urinary outflow symptoms and document the adverse event profile. (2) The patient-contacting components of the device must be demonstrated to be biocompatible. (3) Performance data must demonstrate the sterility of the patient-contacting components of the device. (4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the labeled shelf life. (5) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (i) Deployment and removal; and (ii) Mechanical strength. (6) Labeling must include: (i) Instructions for use, including the recommended training for safe use of the device; (ii) A summary of the clinical performance testing conducted with the device, including device- and procedure-related adverse events; and (iii) A shelf life.
Predicate Devices
- Urocross Expander System (K253525)
Submission Summary (Full Text)
{0}
**FDA** **U.S. FOOD & DRUG**
ADMINISTRATION
June 22, 2026
Prodeon Medical, Inc.
Elaine Aplaon
Sr. Manager, Regulatory Affairs
2200 Zanker Rd., Unit F
San Jose, California 95131
Re: K261342
Trade/Device Name: Urocross Expander System (UES-2018-C1)
Regulation Number: 21 CFR 876.5510
Regulation Name: Temporarily-Placed Urethral Opening System For Symptoms
Of Benign Prostatic Hyperplasia
Regulatory Class: II
Product Code: QKA
Dated: April 23, 2026
Received: April 23, 2026
Dear Elaine Aplaon:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: The Center for Devices and Radiological Health (CDRH) does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the Federal Register.
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
{1}
K261342 - Elaine Aplaon
Page 2
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled 'Deciding When to Submit a 510(k) for a Change to an Existing Device' (https://www.fda.gov/media/99812/download) and 'Deciding When to Submit a 510(k) for a Software Change to an Existing Device' (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ('UDI Rule'). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, 'Misbranding by reference to premarket notification' (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See
{2}
K261342 - Elaine Aplaon
Page 3
the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Mark R. Kreitz -S
for Mark J. Antonino, M.S.
Assistant Director
DHT3B: Division of Reproductive,
Gynecology, and Urology Devices
OHT3: Office of Gastrorenal, ObGyn,
General Hospital, and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
{3}
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.
# Indications for Use
510(k) Number (if known)
K261342
Device Name
Urocross Expander System (Model Number UES-2018-C1)
Indications for Use (Describe)
The Urocross Expander System is intended to relieve urinary outflow obstruction. The Urocross Expander System is indicated for the treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) in men ≥ 45 years old.
The Urocross Expander Implant is indicated for an indwell duration of up to 6 months.
Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (8/23)
Page 1 of 1
PSC Publishing Services (301) 443-6740 EF
{4}
K261342
Page 1 of 4
# **K261342**
**510(k) SUMMARY**
**Urocross Expander System**
# **Contact Details**
**Applicant Name:** Prodeon Medical, Inc.**Applicant Address:** 2200 Zanker Road Ste F
San Jose, CA 95131
United States**Applicant Contact Telephone:** +1 669-467-1100**Applicant Contact:** Elaine Aplaon**Applicant Contact Email:** elaine.aplaon@prodeonmedical.com**Date Prepared:** 22 June 2026
# **Device Name**
**Device Trade Name** Urocross Expander System (Model Number UES-2018-C1)**Common Name:** Temporary Implanted Prostatic Device**Classification Name** Temporarily-placed urethral opening system for symptoms of benign prostatic hyperplasia**Regulation Number:** 21 CFR 876.5510**Product Code(s)** QKA**Predicate Device:** K253525 - Urocross Expander System
# **Device Description**
The Urocross Expander System is a temporary implantable urethral opening system. The Urocross Expander System consists of a sterile, single-use nitinol tissue expander (Urocross Expander Implant) preloaded in a catheter delivery system. The delivery system is made of biocompatible materials widely used in the manufacture of medical devices such as Pebax, stainless steel, polyimide, PTFE, polycarbonate, HDPE, etc. The Urocross Expander System is designed to be
{5}
K261342
Page 2 of 4
advanced through the instrument channel (central through lumen) of a commercially available flexible or rigid cystoscope. The Urocross Expander Implant is then delivered and deployed under cystoscopic visualization in the prostatic urethra. Once deployed in the target location, the expansive strength and stiffness of the Urocross Expander Implant push the lateral lobes apart, increasing the opening of the prostatic urethra lumen, thereby improving urine flow and providing relief from LUTS.
The Urocross Expander Implant is available in one size, 20 mm length x 18 mm diameter (Model/REF Number UES-2018-C1) which is compatible with prostatic urethral lengths of 25-45 mm. The Urocross Expander Implant is designed to be in situ for up to 6 months and can be retrieved at any time during the in-dwell period. Retrieval may be done using the Prodeon Urethral Sheath System and commercially available compatible cystoscopes and graspers commonly used during urological procedures. Alternatively, a rigid cystoscope system and grasper can be used for retrieval.
### Intended Use/Indications for Use
The Urocross Expander System is intended to relieve urinary outflow obstruction. The Urocross Expander System is indicated for the treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) in men ≥ 45 years old.
The Urocross Expander Implant is indicated for an indwell duration of up to 6 months.
### Indications for Use Comparison
The indications for use are identical to that of the predicate device.
### Summary of Technological Characteristics
The Urocross Expander Implant of the subject device is identical to the small Urocross Expander Implant of the predicate device, Model Number ES2018. The Delivery System has been modified for ease of use and ergonomics in the delivery of the Urocross Expander Implant. Both Delivery Systems are comparable in their design/material composition (both are made from biocompatible materials widely used in the medical device industry such as Pebax, stainless steel, polycarbonate, etc.). The subject device Delivery System includes a tether mechanism to control release of the Expander Implant for optimal placement. An Irrigation Connector with Stopcock is included with the subject device Delivery System.
| Urocross Expander System (Subject Device) | Urocross Expander System (Predicate Device) - K253525 |
| --- | --- |
| Temporary nitinol implant for treatment of lower urinary tract symptoms attributed to BPH in men ≥ 45 years old. | Same |
| Indwell up to 6 months. | Same |
{6}
K261342
Page 3 of 4
| Urocross Expander System (Subject Device) | Urocross Expander System (Predicate Device) |
| --- | --- |
| Mechanism of Action: Expand to create an opening in the prostatic urethra through which urine can flow. | Same |
| Deployment Mechanism: Push mechanism to deploy the implant in the prostatic urethra. | Same |
| Implant Material: Nitinol | Same |
| Delivery System: Flexible catheter and handle | Delivery System: Flexible catheter and handle |
| Delivery System Materials: Flexible Catheter: Biocompatible materials widely used in the medical device industry Handle: Biocompatible materials widely used in the medical device industry Includes a tether mechanism to control release of the Expander Implant for optimal placement. Includes a separate Irrigation Connector and Stopcock | Delivery System Materials: Flexible Catheter: Biocompatible materials widely used in the medical device industry Handle: Biocompatible materials widely used in the medical device industry Irrigation connector built into the handle. |
| Removal: Retrieved using Prodeon Urethral Sheath System and commercially available flexible cystoscopes and graspers. Alternatively, the Urocross Expander Implant can be removed using commercially available rigid cystoscopes. | Removal: Same |
| Provided sterile, for single use only. | Same |
| Sterilized by EtO. | Same |
| Biocompatible per ISO 10993-1 | Same |
Both the predicate and the subject device, the Urocross Expander System Model Number UES-2018-C1, share substantially equivalent technological characteristics. The Expander Implant of the subject device is identical to the small Expander Implant of the predicate device. Both Delivery Systems are comparable in their design/material (both are made from biocompatible materials widely used in the medical device industry). The differences between the subject device and the predicate device do not alter the suitability of the subject device for its intended use.
The predicate device has not been subject to a recall.
{7}
K261342
Page 4 of 4
## Non-Clinical Tests Summary & Conclusions
The following bench testing data was provided in support of the substantial equivalence determination:
General performance testing, including:
- Dimensional (ID, OD, Length)
- Irrigation (references: ISO 10555-1: 2013 and ISO 20696:2018)
- Irrigation connector compatibility
- Trackability/kink
- Deployment (Force and Accuracy)
- Tensile Strength (references: ISO 10555-1: 2013 and ISO 20696:2018)
- Leak test
- Expander Implant Radial Force
- Catheter Integrity
- Shelf-life testing to support up to 12 months shelf-life per ASTM F1980-16, ASTM F1886/F1886M-16, ASTM F2096-11, and ASTM F88/F88M-15
The following Biocompatibility testing was performed:
- Cytotoxicity per ISO 10993-5:2009
- Sensitization per ISO 10993-10:2010
- Irritation per ISO 10993-23:2010
Sterilization by ethylene oxide has been validated for the Urocross Expander System in accordance with ISO 11135:2014.
Non-clinical test results demonstrate that the Urocross Expander System meets all predetermined mechanical and functional requirements. Testing performed is appropriate for the design of the Urocross Expander System and similar to the testing performed on the predicate device. Based on the results of the testing, the Urocross Expander System is substantially equivalent to the predicate device.
## Conclusion:
The nonclinical testing of the subject device demonstrates that the Urocross Expander System meets its design requirements and is as safe and effective for its intended use. Based on the results of the testing, the Urocross Expander System is substantially equivalent to the predicate device.
